Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Therapeutics
Ceftobiprole is a new parenterally administered fifth generation cephalosporin which has been shown to have antimicrobial activity against a broad range of bacteria, and specifically against methicillin-resistant Staphylococcus aureus (MRSA) in complicated skin and skin structure infections (cSSSIs), with a cure rate non-inferior to vancomycin and ceftazidime. It has increased stability against β-lactamases and an increased affinity for PBP2 in MRSA strains. Ceftobiprole has shown a low tendency to select for resistance, and because it is excreted mainly in the urine, a low potential for adverse drug interactions. It has been shown to cause few mild to moderate adverse effects in patients. The broad-spectrum of activity makes it an excellent choice for initial monotherapy in cSSSIs. There is also promise for use in all types of pneumonia, and synergistic possibilities with aminoglycoside and fluoroquinolone drugs. It is awaiting final approval by the FDA.
PDF (529.03 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
I would like to express my gratitude and say that publishing in LA's journals is one of the best experiences I have had. I will certainly continue with LA's journals in the future. the unique feature of this publisher is that it provides a research platform for all young researchers. Thank you for providing a sustainable publishing environment for us.